Knowing that this diagnosis can be scary and isolating, Jacquelyn wanted vraniCARE packages to remind people facing breast cancer that they are not alone and that there is so much HOPE. No one but another person who has walked this path before can understand how that feels.
Knowing that this diagnosis can be scary and isolating, Jacquelyn wanted vraniCARE packages to remind people facing breast cancer that they are not alone and that there is so much HOPE. No one but another person who has walked this path before can understand how that feels.
Volunteers needed!
Help with our annual fundraiser or other events throughout the year!
Join the mission of VraniCURE by partnering with us or sponsoring an upcoming event. Learn more about our partnership opportunities.
Research dollars make more treatment options possible, extend our lives and give us more time with our families. Consider donating.
At the age of 38, Jackie attended a routine physical and breast exam, but she sensed that something was amiss. At her request, she underwent an early mammogram, which revealed a tumor and led to a diagnosis of stage IV metastatic breast cancer.
At the age of 38, Jackie attended a routine physical and breast exam, but she sensed that something was amiss. At her request, she underwent an early mammogram, which revealed a tumor and led to a diagnosis of stage IV metastatic breast cancer.
Our mission is to fund lifesaving research for metastatic breast cancer. Our work is directly funding these researchers as they strive to make death from MBC a thing of the past.
Funda Meric-Bernstam, MD —The University of Texas MD Anderson Cancer Center | Presented by Jacquelyn Vranicar & Jacquelyn and Lindsay's METAvivor Team in memory of Kelsey Granowski | Optimizing TROP2-targeted antibody-drug conjugate therapy in metastatic breast cancer
David Kamson, MD, PhD —Sidney Kimmel Comprehensive Cancer at the Johns Hopkins Hospital | Presented by Jacquelyn Vranicar - In Memory of Lindsay Block | A Translational Observational Biorepository and Management Study in Patients with Leptomeningeal Metastasis: The BIOLEPT Study
